ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results
ADC Therapeutics is getting the first pivotal results for the antibody-drug conjugate pipeline that it has spent 8 years and raised $558 million to build — and the company says its lead drug has aced the test.
When given to 145 patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), loncastuximab tesirine induced an overall response rate of 45.5%, including 20% complete responses. Together with a large Phase I, this single-arm, open label Phase II sets ADC Therapeutics up nicely for a BLA later this year, said CEO Chris Martin.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,400+ biopharma pros reading Endpoints daily — and it's free.